SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
EIKN reported Third Quarter 2026 results. The price and volatility reaction is pending.
EIKNearnings

Earnings reactions, page 3

Eikon Therapeutics, Inc. (EIKN) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and marketable securities were $461.7 million as of September 30, 2026.
  • Research and development expenses were $71.8 million for the three months ended September 30, 2026.
  • General and administrative expenses were $18.7 million for the three months ended September 30, 2026.
  • Net loss attributable to common stockholders was $86.1 million for the third quarter of 2026.
  • Net cash used in operating activities was $224.0 million for the nine months ended September 30, 2026.

Guidance

  • Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →